Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results.


Journal Article (Review)

Strategies to delay progression of established renal disease have primarily been directed at examining the class of antihypertensive therapy and/or the level of blood pressure control. In diabetic renal disease many trials have noted a protective role of ACE inhibitor-based therapy over non-ACE inhibitor-based therapy. This paper reviews recent clinical trials evaluating hypertension-related kidney disease including the interim results of the African-American Study of Kidney Diseases and Hypertension (AASK) Study, to date the largest prospective study of African-American patients with kidney disease due to hypertension. This trial reports a renoprotective effect of ACE inhibitor-based therapy over calcium-channel antagonist- based therapy. The renoprotective effect of ACE inhibitor-based therapy may, in part, be due to their antiproteinuric effect independent of blood pressure lowering.

Full Text

Duke Authors

Cited Authors

  • Lea, JP; Brown, DT; Lipkowitz, M; Middleton, J; Norris, K; AASK Study Group,

Published Date

  • 2003

Published In

Volume / Issue

  • 3 / 3

Start / End Page

  • 193 - 200

PubMed ID

  • 14727931

Pubmed Central ID

  • 14727931

International Standard Serial Number (ISSN)

  • 1175-3277

Digital Object Identifier (DOI)

  • 10.2165/00129784-200303030-00005


  • eng

Conference Location

  • New Zealand